About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Metrics: SJR/Scimago (2018): SJR = 0.92. Equivalent Impact Factor = 1.087; International collaboration = 39.96%; ranked 96/324 pharmacology journals worldwide by SJR ranking (14/65 open access titles).

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your manuscript: check the 'SUBMISSION' page for full instructions. Submit your manuscript via Manuscript Manager.

Latest Article

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Edgardo Kaplinsky MD

Articles 2020

Tumor lysis syndrome in childhood malignancies

Wing Lum Cheung MBBS, MRCPCH, Kam Lun Hon MBBS, MD (CUHK), FAAP, FCCM, Cheuk Man Fung MBChB, MRCPCH, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP

Considerations for the US health-system pharmacist in a world of biosimilars

Andrea Zlatkus CRHC, Todd Bixby RPh, Kavitha Goyal MD

Efficacy and safety of photodynamic therapy with RLP068 for diabetic foot ulcers: a review of the literature and clinical experience

Felicia Pantò MD, Liboria Adamo BSc, Carla Giordano MD, Carmelo Licciardello MD

Management of type 2 diabetes: consensus of diabetes organizations

Elaena Quattrocchi BS, PharmD, FASHP, CDE, Tamara Goldberg BS, PharmD, BCPS, Nino Marzella BS, MS, PharmD

Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD

Ramón Novell MD, Susanna Esteba-Castillo PhD, Emili Rodriguez PhD